AstraZeneca unveils second brand play in India
This article was originally published in Scrip
AstraZeneca appears to be the latest to join a clutch of foreign firms deploying the second-brand approach to penetrate the Indian market more effectively.
You may also be interested in...
Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.
An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.
An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.